Crossmark

Cross-Neutralizing Activity of a Live Intranasal Vaccine Based on the Recombinant Sendai Virus of the Moscow Strain against Different Variants of SARS-CoV-2

Crossref DOI link: https://doi.org/10.3103/S0891416825700569

Published Online: 2026-04-01

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kudrov, G. A. https://orcid.org/0000-0002-8251-7040
Zainutdinov, S. S. https://orcid.org/0000-0001-5818-4402
Zaykovskaya, A. V. https://orcid.org/0000-0002-0450-5212
Shulgina, I. S. https://orcid.org/0000-0002-6850-338X
Grazhdantseva, A. A. https://orcid.org/0000-0001-7712-3699
Sivolobova, G. F. https://orcid.org/0000-0002-8362-0314
Bodnev, S. A. https://orcid.org/0000-0003-0599-3817
Sergeev, A. A. https://orcid.org/0000-0001-8355-5551
Kochneva, G. V. https://orcid.org/0000-0002-2420-0483
License Information

Text and Data Mining valid from 2025-12-01

Version of Record valid from 2025-12-01
More Information

Article History

Received: 4 August 2025

Revised: 19 November 2025

Accepted: 19 November 2025

First Online: 1 April 2026

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

: The research followed the principles of biomedical ethics as outlined in the Guidelines for Handing Laboratory (Experimental) Animals when Conducting Preclinical (Non-Clinical) Studies of the Eurasian Economic Community approved November 14, 2023, by the Eurasian Economic Commission Collegium No. 33. The studies were also approved by the Ethics Committee of State Research Center of Virology and Biotechnology “Vector” (protocol no. 7 dated October 27, 2023).

: The authors of this work declare that they have no conflicts of interest.

Document is current

Any future updates will be listed below